FIELD: medicine.
SUBSTANCE: circulating cancer cells are isolated or extracted from a biological sample by vertical filtration through a filter with a pore size between 3 and 100 mcm that allows free circulating tumour rare cells to be retained, but does not prevent passage of smaller cells through the filter. The isolated cells are analyzed by cytomorphology, molecular analysis or DNA and/or RNA analysis. The results of determination are used to diagnose invasive cancer, to select targeted treatment and to monitor development of drug resistance.
EFFECT: non-invasive biological sample test for early diagnosis of invasive cancer in patients with suspected malignant tumours.
20 cl, 4 tbl, 3 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CONDUCTING MULTI-ASSAYS OF RARE CELLS EXTRACTED OR ISOLATED FROM BIOLOGICAL SAMPLES BY FILTRATION | 2013 |
|
RU2765808C2 |
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| INDIVIDUALISED VACCINES FOR CANCER | 2012 |
|
RU2670745C9 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
| REPRESENTATIVE DIAGNOSIS | 2016 |
|
RU2743169C2 |
| MUTATED LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS | 2012 |
|
RU2654673C2 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING LUNG CANCER AGAINST THE BACKGROUND OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2022 |
|
RU2790302C1 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| METHOD FOR PREDICTION OF SURVIVAL RATE IN PATIENTS WITH LUNG ADENOCARCINOMA CARRYING A MUTATION IN THE KRAS GENE | 2019 |
|
RU2702986C1 |
| INDIVIDUALIZED ANTI-TUMOR VACCINES | 2012 |
|
RU2779946C2 |
